Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 28Lymphoid 20Other solid neoplasm 15Gastrointestinal 7Genitourinary 6Dermatologic 4Sarcoma 3Plasma cell 3Breast 3Gynecologic 2Classical hematology 2Thoracic 1Myeloid 1Head & Neck 1CNS 1

Conditions

Thromboembolism 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Head and Neck Neoplasms 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × alvocidib × Head & Neck × Clear all
NCT00020189 2013-06-19

Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Salivary Gland Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡